10th Yunling Breast Cancer Conference | Professor Cexi Chen: Looking Ahead to the Future of Translational Medicine — ADCs, PROTACs, and Organoids as Three Key Priorities to Advance High-Level Breast Cancer Research

10th Yunling Breast Cancer Conference | Professor Cexi Chen: Looking Ahead to the Future of Translational Medicine — ADCs, PROTACs, and Organoids as Three Key Priorities to Advance High-Level Breast Cancer Research

: Breast cancer is one of the most active fields in oncology research and translational medicine. From HER2-targeted therapy to individualized treatment guided by molecular subtyping, numerous basic research discoveries have profoundly transformed clinical practice. During the 10th Yunling Breast Cancer Conference, held in Kunming on August 21–22, 2026, Professor Cexi Chen of Yunnan Cancer Hospital spoke with Oncology Frontier about the directions most likely to drive breakthroughs in basic breast cancer research in China, the key barriers to translating basic discoveries into clinical applications, and the development pathways for young researchers. He highlighted the translational potential of antibody-drug conjugates (ADCs), proteolysis-targeting chimeras (PROTACs), and organoids, emphasizing that breast cancer basic research should always be grounded in unmet clinical needs and should use original technologies with practical value to drive innovation in diagnostic and treatment paradigms.
10th Yunling Breast Cancer Conference | Professor Guojun Zhang: A Decade of Progress, A New Journey Ahead — Molecular Imaging Navigation Empowering Precision Breast Surgery

10th Yunling Breast Cancer Conference | Professor Guojun Zhang: A Decade of Progress, A New Journey Ahead — Molecular Imaging Navigation Empowering Precision Breast Surgery

The 10th Yunling Breast Cancer Conference was held in Kunming from August 21–22, 2026. After a decade of development, the Yunling Breast Cancer Conference has evolved from a regional academic exchange platform into a widely influential breast cancer academic brand. With the theme “Inheritance, Innovation, and Vision,” this year's conference not only brought together leading experts in breast cancer from across China, but also actively incorporated cutting-edge developments from interdisciplinary fields including molecular medicine, artificial intelligence, and materials science, showcasing new advances in breast cancer basic research and clinical practice.
10th Yunling Breast Cancer Conference | Professor Yehui Shi: From “Targeting What Can Be Targeted” to Moving ADCs Forward — Reshaping the Precision Treatment Pathway for Advanced HR+/HER2− Breast Cancer

10th Yunling Breast Cancer Conference | Professor Yehui Shi: From “Targeting What Can Be Targeted” to Moving ADCs Forward — Reshaping the Precision Treatment Pathway for Advanced HR+/HER2− Breast Cancer

HR+/HER2− breast cancer is the most common molecular subtype of breast cancer, and the combination of CDK4/6 inhibitors and endocrine therapy has become an important standard first-line treatment for patients with advanced disease. With the increasing availability of PI3K/AKT/mTOR (PAM) pathway inhibitors, novel endocrine therapies, and antibody-drug conjugates (ADCs), the treatment of advanced HR+/HER2− breast cancer is gradually evolving from a relatively fixed sequential treatment model toward precision stratification based on molecular characteristics.
Director Ying Jiang: Optimizing the Combination of Transplantation and CAR-T Therapy to Explore New Pathways for Immunotherapy in Hematologic Malignancies | Gaobo Medical Forum 2026

Director Ying Jiang: Optimizing the Combination of Transplantation and CAR-T Therapy to Explore New Pathways for Immunotherapy in Hematologic Malignancies | Gaobo Medical Forum 2026

From August 29–30, 2026, the “Gaobo Medical Forum — 6th Clinical Application Symposium and Training Course on Autologous Hematopoietic Stem Cell Transplantation,” organized by the National Clinical Research Center for Blood Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and hosted by Shanghai Zha Xin Hospital/Shanghai Liquan Hospital of Gaobo Medical Group, was held in Shanghai. During the meeting, Oncology Frontier – Hematology Frontier invited Director Ying Jiang of Gaobo Shanghai Zha Xin Hospital to share insights into her team’s innovative combination treatment strategies for relapsed/refractory hematologic malignancies, as well as their latest explorations and clinical experience in the comprehensive safety management of CAR-T cell therapy.
Professor Wei Xu: Differential Diagnosis of Lymphoproliferative Disorders丨2026 Cross-Strait Hematology Academic Conference

Professor Wei Xu: Differential Diagnosis of Lymphoproliferative Disorders丨2026 Cross-Strait Hematology Academic Conference

Differential diagnosis of chronic lymphoproliferative disorders (CLPD) remains a major challenge in hematology. Given the blurred boundary between reactive lymphoid proliferation and clonal proliferation, as well as the substantial overlap in morphological and immunophenotypic features among different subtypes, avoiding misdiagnosis and missed diagnosis is of critical importance. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Professor Wei Xu of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) to systematically explain the diagnostic approach integrating basic morphology, flow cytometric immunophenotyping, and molecular genetic testing. Professor Xu also provided an in-depth analysis of strategies for resolving challenging CLPD cases, offering authoritative guidance for clinicians to establish a standardized, multidimensional, and precise classification system for these disorders.
the 14th Lu Daopei Hematology Forum | Professor Yuqian Sun: Precision Assessment, Tailored Strategies — Current Status and Future Directions of Hematopoietic Stem Cell Transplantation in Older Patients

the 14th Lu Daopei Hematology Forum | Professor Yuqian Sun: Precision Assessment, Tailored Strategies — Current Status and Future Directions of Hematopoietic Stem Cell Transplantation in Older Patients

Bringing together leading experts in Hebei and staying true to its mission for 14 years. On August 21, 2026,the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic experience, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across China gathered to discuss the development of the field, making the conference an important academic platform for advancing hematologic disease diagnosis and treatment in China. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Yuqian Sun of Peking University People's Hospital, who shared her expert insights on the current status of hematopoietic stem cell transplantation in older patients, as well as patient assessment and selection strategies.
the 14th Lu Daopei Hematology Forum | Professor Xingyu Cao: Precision Risk Stratification, Optimized Strategies — Advances and Strategies in Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes

the 14th Lu Daopei Hematology Forum | Professor Xingyu Cao: Precision Risk Stratification, Optimized Strategies — Advances and Strategies in Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes

Bringing together leading experts in Hebei and staying true to its mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic experience, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across China gathered to discuss the development of the field, making the conference an important academic platform for advancing hematologic disease diagnosis and treatment in China. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Xingyu Cao of Lu Daopei Hospital, who shared her expert insights on the role of transplantation in myelodysplastic syndromes (MDS), the timing of transplantation, advances in conditioning regimens, and strategies for preventing relapse.
Roundtable · Moments in Time | Hematology Experts from Mainland China, Taiwan, Hong Kong and Macao: Looking Back on Cross-Regional Exchange, Carrying Forward a Shared Legacy, and Shaping a Future of Collaboration

Roundtable · Moments in Time | Hematology Experts from Mainland China, Taiwan, Hong Kong and Macao: Looking Back on Cross-Regional Exchange, Carrying Forward a Shared Legacy, and Shaping a Future of Collaboration

Medical progress is driven not only by clinical practice and scientific innovation, but also by cross-regional exchange, mutual learning, and the transmission of knowledge and experience. Looking back at the history of hematology collaboration among the Chinese mainland, Taiwan, Hong Kong, and Macao—from the “seeds of life” transported across the Taiwan Strait to continuous breakthroughs in transplantation technology, and from exchanges among young physicians to deepening medical collaboration—each interaction has contributed to advances in diagnosis and treatment and enabled more patients to benefit from improved care.
Professor Zhang Xiaohui Elected Vice Chair-Elect of the Hematology Branch of the Chinese Medical Association

Professor Zhang Xiaohui Elected Vice Chair-Elect of the Hematology Branch of the Chinese Medical Association

On December 23, 2024, the Hematology Branch of the Chinese Medical Association held its committee transition meeting in Beijing, where the 12th Committee, consisting of 87 members, was elected. Following individual presentations and a secret ballot by all committee members, Professor Zhang Xiaohui, Deputy Director and Director of the Office of the National Clinical Research Center for Hematologic Diseases, Deputy Director of the Peking University Institute of Hematology, and Professor of Hematology at Peking University People's Hospital, was elected Vice Chair-Elect of the Hematology Branch. Professor Jiang Qian and Professor Chang Yingjun were also elected as committee members.